Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

Clinical and Experimental Metastasis

Volumn 33, Issue 4, 2016, Pages 325-337

  Valta, Maija P ^a,b   Zhao, Hongjuan ^a   Saar, Matthias ^a,c   Tuomela, Johanna ^d   Nolley, Rosalie ^a   Linxweiler, Johannes ^c   Sandholm, Jouko ^d   Lehtimäki, Jaakko ^d   Härkönen, Pirkko ^d   Coleman, Ilsa ^e   Nelson, Peter S ^e,f   Corey, Eva ^f   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF TURKU   (Finland)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen dependence; Bone metastasis; Osteosclerosis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HERMES ANTIGEN; OSTEOCALCIN; PROTEIN P53; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOSCLEROSIS; PATIENT DERIVED XENOGRAFT; PHENOTYPE; PROSTATE CANCER; TUMOR GROWTH; TUMOR SPHEROID; TUMOR VOLUME; XENOGRAFT; ANIMAL; BONE TUMOR; DRUG SCREENING; METASTASIS; MULTICELLULAR SPHEROID; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; MALE; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SPHEROIDS, CELLULAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957940896     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-016-9781-2     Document Type: Article

References (44)

1. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11(6):411–425
2. Groot MT et al (2003) Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 43(3):226–232
3. Lange PH, Vessella RL (1998) Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17(4):331–336
4. Parker C et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223
5. Mohler JL et al (2014) Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12(5):686–718
6. Crawford ED et al (2015) Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol 194(6):1537–1547
7. Ocana A et al (2011) Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 8(4):200–209
8. Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351–3354 (discussion 4)
9. Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 173(2):342–359
10. Najy AJ et al (2012) Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 72(12):1328–1338
11. Valta MP et al (2008) FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 123(1):22–31
12. Bonfil RD et al (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170(6):2100–2111
13. van Weerden WM, Bangma C, de Wit R (2009) Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 100(1):13–18
14. Young SR et al (2013) Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate 73(12):1251–1262
15. Barbieri CE et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685–689
16. Saar M et al (2014) Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett 351(2):272–280
17. Ibrahim L, Wright EA (1983) Effect of castration and testosterone propionate on mouse vibrissae. Br J Dermatol 108(3):321–326
18. Saar M et al (2012) Experimental orthotopic prostate tumor in nude mice: techniques for local cell inoculation and three-dimensional ultrasound monitoring. Urol Oncol 30(3):330–338
19. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675
20. Kumar A et al (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 108(41):17087–17092
21. Wettenhall JM, Smyth GK (2004) limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20(18):3705–3706
22. Leek JT et al (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883
23. Leeming DJ et al (2011) Serum N-terminal propeptide of collagen type i is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers. Biomark Cancer 3:15–23
24. Edwards JR, Mundy GR (2011) Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7(4):235–243
25. Zhang X et al (2015) Amplification and protein expression of androgen receptor gene in prostate cancer cells: fluorescence hybridization analysis. Oncol Lett 9(6):2617–2622
26. Ayala G et al (2015) Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer 22(3):277–287
27. Adley BP, Yang XJ (2006) Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol 28(1):1–13
28. Simmons JK et al (2015) Animal models of bone metastasis. Vet Pathol 52(5):827–841
29. Ganguly SS, Li X, Miranti CK (2014) The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol 4:364
30. Nemeth JA et al (1999) Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59(8):1987–1993
31. Graham TJ et al (2014) Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 106(4):dju033
32. Yang J et al (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652–5659
33. Hagberg Thulin M et al (2014) Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis 31(3):269–283
34. Li ZG et al (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Investig 118(8):2697–2710
35. Roychowdhury S et al (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra21
36. Larson SR et al (2013) Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 73(9):932–940
37. Brennecke P et al (2014) CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin Exp Metastasis 31(3):339–349
38. Drake CG (2014) Visceral metastases and prostate cancer treatment: ‘die hard’, ‘tough neighborhoods’, or ‘evil humors’? Oncology (Williston Park) 28(11):974–980
39. Akfirat C et al (2013) Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol 230(3):291–297
40. Morrissey C et al (2010) Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 70(16):1799–1808
41. Brubaker KD et al (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15
42. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT (2013) Of mice and men–warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 73(12):1316–1325
43. Gonzalez-Billalabeitia E et al (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4(8):896–904
44. Semenas J et al (2014) The role of PI3K/AKT-related PIP5K1alpha and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci USA 111(35):E3689–E3698